Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

Clonal replacement and heterogeneity in breast tumors treated with neoadjuvant HER2-targeted therapy

When examining the evolution of treatment resistance in breast cancer, perceived genomic changes may be due to clonal evolution or heterogeneous tumors. Here, the authors show that apparent clonal change can in fact be due to pre-treatment heterogeneity, and samples from at least two regions are nec...

Full description

Bibliographic Details
Main Authors: Jennifer L. Caswell-Jin, Katherine McNamara, Johannes G. Reiter, Ruping Sun, Zheng Hu, Zhicheng Ma, Jie Ding, Carlos J. Suarez, Susanne Tilk, Akshara Raghavendra, Victoria Forte, Suet-Feung Chin, Helen Bardwell, Elena Provenzano, Carlos Caldas, Julie Lang, Robert West, Debu Tripathy, Michael F. Press, Christina Curtis
Format: Article
Language:English
Published: Nature Publishing Group 2019-02-01
Series:Nature Communications
Online Access:https://doi.org/10.1038/s41467-019-08593-4

Internet

https://doi.org/10.1038/s41467-019-08593-4

Similar Items